This company has shut down. Point Biopharma is no longer operating — its last tracked round was a Post-IPO Equity in 2022.
Explore the Startup GraveyardPoint Biopharma focused on the development and commercialization of radioligand therapies for the treatment of cancer.
Point Biopharma has raised $125.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2022.
Point Biopharma's investors include RA Capital Management, Perceptive Advisors, Farallon Capital Management, Fairmount Funds Management, Biotechnology Value Fund.
Point Biopharma is headquartered in Indianapolis, United States.
Point Biopharma focused on the development and commercialization of radioligand therapies for the treatment of cancer.
Point Biopharma is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Point Biopharma — Funding & Investors." VCBacked, September 13, 2022, https://www.vcbacked.co/company/point-biopharma. Accessed September 30, 2026.
VCBacked. (2022). Point Biopharma — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/point-biopharma
{{cite web |title=Point Biopharma — Funding & Investors |url=https://www.vcbacked.co/company/point-biopharma |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated